The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

LSU researchers discover key immune differences in TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers at the LSU LCMC Health Cancer Center examined tumors from more than 250 Black and white women across Louisiana and uncovered key immune differences in patients with triple-negative breast cancer, one of the most aggressive forms of breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

“Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant side effects. This creates a critical need for strategies that localize their toxic activity to tumors. What if cancer drugs could stay dormant until they reach cancer cells? A study by Syracuse University researchers demonstrates a promising chemistry-based strategy that could do just that.
Clinical Roundup

Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer

Androgen receptor alterations consistently emerged in serial liquid biopsies researchers used to track how metastatic prostate cancer evolves under treatment pressure. These alterations were linked to poorer outcomes across therapies, according to a multi-center collaboration of investigators from Sylvester, UC San Diego, Moores Cancer Center, the University of California, San Francisco, Scripps Research Institute, and Guardant Health. 
Clinical Roundup

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account